Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

1
Player Avatar 1760mill (23.97) Submitted: 9/15/2006 2:56:55 AM : Outperform Start Price: $24.38 PGNX Score: -137.63

Drug for opioid-induced constipation has had very good trial results. FDA submission next year. Also discovered receptor HIV uses to enter cells, a potential blockbuster drug target, but still pretty far off.

Featured Broker Partners


Advertisement